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Abstract
Introduction—Chronic hypersecretion of the 37 amino acid amylin is common in type 2 
diabetics (T2D). Recent studies implicate human amylin aggregates cause proteotoxicity (cell 
death induced by misfolded proteins) in both the brain and the heart.
Objectives—Identify systemic mechanisms/markers by which human amylin associated with 
cardiac and brain defects might be identified.
Methods—We investigated the metabolic consequences of amyloidogenic and cytotoxic amylin 
oligomers in heart, brain, liver, and plasma using non-targeted metabolomics analysis in a rat 
model expressing pancreatic human amylin (HIP model).
Results—Four metabolites were significantly different in 3 or more of the the four compartments 
(heart, brain, liver, and plasma) in HIP rats. When compared to a T2D rat model, HIP hearts 
uniquely had significant DECREASES in five amino acids (lysine, alanine, tyrosine, 
phenylalanine, serine), with phenylalanine decreased across all four tissues investigated, including 
plasma. In contrast, significantly INCREASED circulating phenylalanine is reported in diabetics 
in multiple recent studies.
Conclusion—DECREASED phenylalanine may serve as a unique marker of cardiac and brain 
dysfunction due to hyperamylinemia that can be differentiated from alterations in T2D in the 
plasma. While the deficiency in phenylalanine was seen across tissues including plasma and could 
be monitored, reduced tyrosine was seen only in the brain. The 50% reduction in phenylalanine 
and tyrosine in HIP brains is significant given their role in supporting brain chemistry as a 
precursor for catecholamines (dopamine, norepinephrine, epinephrine), which may contribute to 
the increased morbidity and mortality in diabetics at a multi-system level beyond the effects on 
glucose metabolism.
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1 Introduction
Amylin, or Islet amyloid polypeptide, is a 37 amino acid hormone, co-secreted with insulin 
from β- cells in the pancreatic Islets of Langerhans. Since its discovery in 1986, research 
identifying amylin’s regulatory effects on nutrient fluxes, satiation, and on the regulation of 
insulin and pancreatic beta cells have been reported (Hay et al. 2015). In addition to its 
emerging physiological roles, chronic hypersecretion of amylin is an emerging concern as it 
is common in pre-diabetic and obese humans (Despa et al. 2012; Despa et al. 2014). Recent 
studies have demonstrated that human amylin aggregates in vivo to cause proteotoxicity (cell 
death induced by misfolded proteins) in both the brain and the heart (Despa et al. 2012; 
Despa et al. 2014; Srodulski et al. 2014).
These studies have redefined the relationship between type II diabetes and 
neurodegenerative disease. As the most common form of dementia, Alzheimer’s disease is 
characterized by the accumulation of extracellular beta amyloid peptide aggregates and 
intracellular hyperphosphorylated tau protein (Verdile et al. 2015). Recent studies have 
identified amylin oligomers and plaques in the temporal lobe gray matter from diabetic 
patients, but not controls (Jackson et al. 2013). Interestingly, while amylin accumulation lead 
to amyloid formation independent of amyloid beta deposition, tissues infiltrated by amylin 
occasionally mixed with amyloid beta protein, the typical pathogenic lesion in Alzheimer’s 
disease (Jackson et al. 2013). Amylin infiltration in these patients were widespread, 
evidenced by increased interstitial space, vacuolation, spongiform changes, and capillaries 
bent at amylin accumulation sites without evidence of synthesis in the brain (Jackson et al. 
2013). These findings have led to the hypothesis that human amylin has a role at the 
interface between metabolic and neurodegenerative disorders which are widely 
underestimated (Lutz, Meyer 2015).
In the present study, we investigated the metabolic consequences of amyloidogenic and 
cytotoxic amylin oligomers and diabetes in the multiple organs applying non-targeted 
metabolomics analysis to a recently created rat model expressing pancreatic human amylin 
(HIP model). Since rodent amylin has been found to be uniquely non-amyloidogenic and 
non-cytotoxic in contrast to human amylin, rats expressing human amylin in the pancreas 
(HIP) have previously been utilized to elucidate that oligomerized amylin migrates to most 
organs, including the heart and brain (Despa et al. 2014; Lambert et al. 2015; Srodulski et al. 
2014). Compared to littermate wildtypeHIPTg+ rats, the HIP rats have defects in the pancreas 
over time, leading to diabetes and brain/heart dysfunction secondary to the accumulation of 
oligomerized amylin, including large deposits of >50 microns in the brain (Srodulski et al. 
2014). The hyperamylinemia-induced oligomerized amylin further mediated activation of 
inflammation, leading to neurologic defects manifesting as reduced exploratory drive, 
impaired recognition memory, and the lack of ability to improve rotarod performance (an 
assay of body balance) (Srodulski et al. 2014). Cardiac defects are seen in parallel, Na+ 
influx significantly larger in HIP myocytes compared to wildtypeHIPTg+ controls, resulting 
in arrhythmogenesis and oxidative stress (Lambert et al. 2015). To delineate how human 
amylin affects the heart, brain, and liver we performed non-targeted metabolomics on 12-
month-old HIP rats along with non-targeted analysis of plasma to identify if the metabolic 
changes seen in tissues are paralleled in the circulation as biomarkers of disease.
Ilaiwy et al. Page 3
Metabolomics. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
2 Materials and Methods
2.1 Transgenic HIP rat model
The investigation conforms to the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) 
and was approved by the Institutional Animal Care and Use Committees at University of 
Kentucky. Male HIP rats at one year of age were used in the present study and are Sprague–
Dawley rats expressing human amylin in pancreatic β-cells. This model was previously used 
to study complications of T2D associated with amylin deposition in myocardium (Despa et 
al. 2012; Erickson et al. 2013) and brain (Srodulski et al. 2014). Age- and gender-matched 
wild type littermates (wildtypeHIPTg+) do not accumulate pancreatic or peripheral amylin 
and served as controls. The tissue assayed and the glucose determinations in the current 
study are exclusive newly generated data.
2.2 Metabolomics Determination by GC–MS Instrumentation
Cardiac tissue was flash frozen in a liquid nitrogen cooled biopress, weighed (25–50 mg wet 
weight), then placed in buffer (50 % acetyl-nitrile, 50 % water, 0.3 % formic acid) at a 
standard concentration of 25 mg/475 mcl buffer then fully homogenized on ice for 10–25 s 
and placed on dry ice/stored at −80C. Samples were then analyzed by GC/MS, as previously 
described (Banerjee et al. 2015). The raw, transformed, and sorted data used for each of the 
three comparisons in the metabolomics analyses can be found in Supplemental Table 1. Up 
to 3 missing values per group were imputed using lowest value in the same group, with 
groups missing 4 or more excluded from the analysis. In groups where the analyte was 
missing in all members, a value of 1 was imputed for statistical analysis, with their fold 
change interpreted with caution as indicated in Figures 1–4 (*, e.g. Inosine 5′ 
monophosphate in Figure 1A). All data used in this analysis has been archived in the UCSD 
Metabolomics Workbench (http://www.metabolomicsworkbench.org/), accession 
#PendingAssignment/Uploaded 17 February 2016.
2.3 Metabolomic Statistical Analyses
Metaboanalyst (v3.0) run on the statistical package R (v2.14.0) used metabolite peaks areas 
(as representative of concentration) (Xia et al. 2009; Xia et al. 2015). These data were first 
analyzed by an unsupervised principal component analysis (PCA), which identified the 
presence of the human islet amyloid polypeptide (hIAPP)-amylin as the principal source of 
variance. The metabolites that best differentiated the groups were then individually tested 
using the Univariate analysis of individual component by t-test (Metaboanalyst v 3.0), and 
then the t test significant metabolites were matched to metabolomics pathways using the 
Pathway Analysis and enrichment analysis features in Metaboanalyst 3.0. To detect systemic 
metabolic signature of amylin, a One-Way Analysis of Variance (ANOVA) across the eight 
tissues and genotypes was performed (wildtypeHIPTg+ heart, HIPTg+ heart, wildtypeHIPTg+ 
brain, HIPTg+ brain, wildtypeHIPTg+ liver, HIPTg+ liver, wildtypeHIPTg+ plasma, and 
HIPTg+ plasma) using Metaboanalyst v3.0, including both false discovery rate and 
significance (p). Only metabolites identified and detected in all groups were included in the 
One-Way ANOVA. If four or more values of each metabolite were missing in a given group, 
the entire metabolite was removed from the analysis. Only metabolites significantly altered 
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in 2 or more organs were plotted to show systemic alterations induced by amylin. Data used 
in this study are available in Supplemental Table 1.13. Heat maps were generated using the 
GENE- E software (http://www.broadinstitute.org/cancer/software/GENE-E/index.html). All 
data is shown as mean +/− SEM, unless otherwise indicated.
2.4 Validation study
In order to differentiate amylin metabolic effect from diabetic metabolic signature, we 
compare our results with published non-targeted metabolomic datasets obtained from type 2 
diabetic hearts (Kouzu et al. 2015). PubMed was searched using the terms “Metabolomics” 
“heart” “type 2 diabetes” and “rat”, resulting in two articles. We chose the dataset from 
Kouzu, et al., 2015 (Kouzu et al. 2015) for its similarity of T2D and baseline controls 
clinically. Metabolites identified in both our study and the Kouzu et al., 2015 (Kouzu et al. 
2015). The four groups compared were: (1) wildtypeHIPTg+; (2) HIPTg+; (3) lean wildtype 
controls/Long-EvansTokushima-Otsuka/LETO; and (4) T2D/Otsuka Long-Evans Tokushima 
fatty/OLETF. Data were analyzed using SigmaPlot 11.0 after normalization to their 
respective wildtype controls (wildtypeHIPTg+ and LETO) and plotted as the mean +/− SEM. 
Raw data used in this validation study are available in Supplemental Table 2.
3 Results
Blinded non-targeted metabolomics analysis of cardiac samples identified and named 100 
metabolites (Figure 1A). Using an unsupervised PCA analysis, the HIP cardiac metabolites 
separated into distinct population, with 47.7% of the differences accounted for by principal 
component 1 (Figure 1B). T-test analysis of these cardiac HIP metabolites identified 45 as 
significantly different (p<0.05) (Figure 1C) Of the significantly altered metabolites in HIP 
hearts, many are amino acids, including phenylalanine (0.5 fold wildtypeHIPTg+), tyrosine 
(0.5 fold wildtypeHIPTg+), glycine (0.5 fold wildtypeHIPTg+), serine (0.25 fold 
wildtypeHIPTg+), and lysine (not detected vs. detected in wildtypeHIPTg+)(Figure 1C). 
Pathway analysis enrichment of the t-test significant metabolites revealed the highest 
enrichment (~7-fold enrichment) in: 1) protein biosynthesis; 2) alpha-linolenic and linoleic 
acid metabolism; 3) Glycolysis; and 4) phenylalanine and tyrosine metabolism 
(Supplemental Figure 1A). Analysis against location based enrichment identified ~10 fold 
enrichment in “Basal Ganglia” metabolites, then lysosome, mitochondria, and skeletal 
muscle (Supplemental Figure 1B).
Blinded non-targeted metabolomics analysis of HIP brain samples identified and named 144 
metabolites (Figure 2A). Unsupervised PCA analysis identified overlap between the HIP and 
wildtypeHIPTg+ brain metabolite signature (Figure 2B), with 30 t-test significant metabolites 
identified (Figure 2C). Similar to the cardiac metabolomics findings, the pathway 
enrichment analysis identified enrichment in the protein synthesis pathway (Supplemental 
Figure 2A). In addition, gluconeogenesis, phenylalanine/tyrosine metabolism, and the 
pentose metabolism pathways were highly enriched (>= 4 fold enrichment) (Supplemental 
Figure 2A). Like the heart, pathway analysis for location enrichment found a >15 fold 
enrichment in “Basal Ganglia” metabolites, along with muscle and skeletal muscle (~2 fold) 
(Supplemental Figure 2B). Interestingly, analysis against CSF metabolite pathways 
Ilaiwy et al. Page 5
Metabolomics. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
identified an 8-fold enrichment in “2-methyl-3 hydroxbutryl-CoA dehydrogenase (MHBD) 
deficiency” and “phenylketonuria” (Supplemental Figure 2C).
Blinded non-targeted metabolomics analysis of HIP liver samples identified multiple 
metabolites that were not present in wildtypeHIPTg+ control rats, including cystine, 5-
aminovaleric acid, cytidine-5′-monophosphate, and phytol along with elevated propylene 
glycol (Figure 3A). These metabolites demonstrated distinct signatures by PCS analysis 
(Figure 3B), and the uniquely present HIP liver metabolites identified (i.e. not found in 
wildtype livers) ranked among the top many t-test significant metabolites (Figure 3C). 
Pathway analysis revealed that alpha linolenic acid and linoleic acid metabolism, 
gluconeogenesis, and glycerolipid metabolism were the highest enriched (>3 fold, 
Supplemental Figure 3A). Location enrichment analysis identified “Basal Ganglia”, as in the 
brain prior, enriched ~7 fold (Supplemental Figure 3B).
In contrast, the differences in the non-targeted metabolomics analysis of parallel HIP plasma 
(Figure 4A) overlapped by PCA analysis (Figure 4B) and had only 16 t-test significant 
metabolites (Figure 4B). As identified in the heart and brain, protein biosynthesis was the 
most significantly enriched pathway (~7 fold), with biotin metabolism was also highly 
enriched >15 fold (Supplemental Figure 4).
To understand the metabolic signatures identified across the different organ systems, we next 
performed an ANOVA comparing heart, brain, liver, and plasma in HIP and wildtype rats (8 
groups total). With a false discovery rate (FDR)<1ˆ10−9, we identified that fumarate (Figure 
6A), phenylalanine (Figure 6B), α-monstearin (Figure 6C), and uracil (Figure 6D) were 
significantly different in the HIP heart, brain, and liver. Phenylalanine was uniquely 
decreased in the plasma as well, making it the only metabolite DECREASED in all four 
compartments tested in the HIP model (Figure 6B). In this same ANOVA analysis, eight 
additional metabolites were significantly elevated in at least two compartments (Table 2), 
with lysine being the only one additionally found in plasma. While the ANOVA analysis 
across all four organs allowed the direct comparison of amino acids identified in all organs, 
there were multiple amino acids that were not detected in at least one organ (Supplemental 
Table 2, primarily right half of table). Significant alterations were seen in glutamic acid 
(heart and Liver), ornithine, cysteine and cystine (Liver only) (Supplemental Table 2).
One of the complexities of the HIP model studied here is the fact that while the HIP rats are 
not initially diabetic, they develop diabetes as the proteotoxicity of the human amylin kills 
the pancreatic beta cells. Distinguishing the metabolic signatures of the type 2 diabetes from 
the amylin proteotoxicity component was what we next addressed using a published non-
targeted metabolomics data set in a type 2 diabetes rat model recently published (Kouzu et 
al. 2015). Using an ANOVA analysis of the cardiac HIP (and strain-matched wildtype) 
significant metabolites with the recently published T2D (and strain-matched wildtype) 
significant metabolites revealed that both models had similar significant decreases in glycine 
(HIP vs. T2D p>0.05; HIP vs. wildtypeHIPTg+ p=0.001, T2D vs wildtypeT2D p=0.028) and 
similar significant increases in leucine (Figure 6, indicated with boxes). This confirms the 
expected overlap of the HIP and T2D models. Interestingly, we identified eight metabolites 
that were significantly different in the HIP heart, but not in the T2D heart: including 
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pyruvate, malate, citrate, fumarate, urea, glycerol-1-phosphate, fructose-6-phosphate, 
glucose-6-phosphate, and hypoxanthine (Figure 6A, indicated by *). Significantly altered 
amino acids found in the HIP heart, but not in the T2D heart, including: lysine, alanine, 
tyrosine, phenylalanine, serine, threonine, glutamic acid, and valine (Figure 6B, indicated by 
*). Uniquely, HIP heart had significantly INCREASED fructose-6-phosphate and glucose-6-
phosphate, which was not seen in the T2D hearts (Figure 6A). The HIP heart had 
significantly DECREASED alanine, tyrosine, and phenylalanine in contrast to the 
significantly INCREASED levels of these amino acids in the T2D hearts (Figure 6B).
4 Discussion
In contrast to previous studies illustrating alterations in amino acid levels in just the diabetic 
heart, the current studies demonstrate that these changes occur systemically across multiple 
organs (heart, brain, liver, plasma, Figure 6, Supplemental Table 3). Protein biosynthesis was 
the highest enriched pathway in the HIP heart and brain, with a greater than five-fold 
enrichment by pathway analysis (Supplemental Figures 1 & 2). Alterations in phenylalanine 
metabolism and aminoacyl-tRNA biosynthesis were specifically identified as affected 
(Supplemental Figure 5A, 5D). These studies build upon sparse reports of decreased 
phenylalanine in diabetic hearts (Rampersad, Wool 1965), increased protein degradation in 
muscle (Ashford, Pain 1986), and alterations in mitochondrial protein synthesis (Boirie et al. 
2001). The present study illustrates that changes in tyrosine metabolism are affected more 
widely, including tyrosine decreases in heart (Figure 5A), phenylalanine decreases in heart 
and Liver and increased fumarate, a degradation product of tyrosine/phenylalanine 
metabolism (Figure 5A, Figure 6A). Evidence for increased protein degradation comes from 
the finding that there is increased tyrosine/phenylalanine degradation product fumarate 
(Figure 5A, Figure 6A), and the finding that urea and intermediates of the urea cycle are 
increased (Figure 5B, Figure 6B). As systemic protein degradation is a major up-regulator of 
urea cycle in diabetes (Jorda et al. 1982; Li et al. 2010; Schutz 2011), the present findings 
may demonstrate a relationship here in linking amylin and diabetes with the urea cycle 
changes identified here. Given the close connection between increased protein catabolism, 
morbidity and increased hospital stay and mortality, the connection between diabetes in 
chronic and acute diseases may lie in processes beyond the effects on glucose metabolism 
(Pasini et al. 2014; Pasini et al. 2013).
The comparison of non-targeted metabolomics found in the HIP rat heart compared to a 
strictly T2D model in the present study identified unique metabolomics alterations in the 
HIP heart not attributable to T2D (Supplemental Figure 6). HIP hearts exhibited significant 
increases in TCA cycle metabolites (pyruvate and urea) and metabolites involved in 
gluconeogenesis (glycerol-1-phosphate, fructose-6-phosphate, and glucose-6-phosphate)
(Supplemental Figure 6A). HIP hearts exhibited significant alterations in amino acids, with 5 
being significantly DECREASED (lysine, alanine, tyrosine, phenylalanine, serine) and 1 
INCREASED (valine) compared to T2D (Supplemental Figure 6B). This contrasts with the 
significantly INCREASED phenylalanine reported in diabetics vs. controls in multiple 
recent studies (Kouzu et al. 2015; Tillin et al. 2015; Wurtz et al. 2015). The HIP rats at one 
year exhibited this significant decreases across all four tissues investigated, including plasma 
(Figure 6). This illustrates that DECREASE phenylalanine may be worth following as it 
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correlates with HIP induced cardiac and brain dysfunction, but unrelated to the presence of 
T2D.
The deficiency in phenylalanine and tyrosine in HIP brains (<0.50 fold vs. wildtypeHIPTg+) 
is significant given their role in supporting brain chemistry (Figure 2). Tyrosine (and its 
precursor phenylalanine) in the brain function as precursors for catecholamines (dopamine, 
norepinephrine, epinephrine) (Fernstrom, Fernstrom 2007). Deficiency in dopamine, 
requiring these metabolites, contributes to early visual dysfunction in experimental type 
1diabetes (Aung et al. 2014). Other studies of experimental type 1 diabetes have 
demonstrated that brain phenylalanine is decreased by an average of 40% throughout the 
entire brain, with a depressed influx of 35%, suggesting these decreases are due to transport 
defects (Mans et al. 1987). The detection of elevated brain ketones, such as beta-
hydroxybutyric acid in HIP mice nearly 4-fold, is not unexpected given their diabetic status 
(Figure 2B). Cerebral beta-hydroxybutyric acid has been detected by MR spectroscopy in 
children with diabetic ketoacidosis (Wootton-Gorges et al. 2005) and in other rat models 
(Reusch et al. 2003), which alters glucose metabolism, glutamine, glutamate, and GABA 
(Lapidot, Haber 2001).
Interestingly, the alterations in the pentose phosphate pathway (PPP) that were identified in 
the brain in the current study (Figure 2, i.e. glucose-6-phosphate elevated 4.7 fold, 
fructose-6-phosphate elevated 5.3 fold) have previously been seen in the brain in 
neurodegenerative diseases. Unlike most other cell types, neurons preferentially metabolize 
glucose using the pentose phosphate pathway to maintain their anti-oxidant status. Inhibiting 
this pathway results in selective dopaminergic cell death leading to motor deficits 
resembling Parkinson’s disease (Dunn et al. 2014). In Parkinson’s disease brain tissues, 
down-regulation of PPP enzymes and failure to increase antioxidant reserve is an early event 
in the pathogenesis of sporadic Parkinson’s disease (Dunn et al. 2014), which parallels 
findings of reduced pentose phosphate fluxes are reduced in amyloid beta protein precursor 
(AbetaPP) mice and Alzheimer’s disease patients (Tiwari, Patel 2014). Importantly, these 
alterations are not characteristic of diabetes. Since the hyperamylinemia modeled in the 
present HIP model demonstrated neurodegenerative plaques (Srodulski et al. 2014) and 
amylin co-staining with tau protein to accelerate the (Jackson et al. 2013; Qiu et al. 2014). 
Therefore, the present studies may offer mechanistic detail of amylin-driven pathology apart 
from the diabetes-associated pathology both seen in the present animal model.
Similar to the metabolites found in the brain that were linked to hyperamylinemia-induced 
proteotoxicity, the identification of cystine uniquely in the HIP liver (Figure 3) was 
interesting as it has been identified in previously studies as a potential biomarker of 
Alzheimer’s Disease (Gonzalez-Dominguez et al. 2015). As an important metabolic 
intermediate in glutathione metabolism, cystine may offer clues to oxidative stress not 
previously reported in the liver. While its not surprising to see alterations in anti-oxidant 
systems in the HIP rats given the inflammatory nature of diabetes in general and in this 
model specifically (Srodulski et al. 2014), the increased in the reduced 5-aminovaleric acid 
has been used to detect oxidative stress in atherosclerotic lesions by GC-MS (Pietzsch et al. 
2004).
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Recent studies applying non-targeted metabolomics to hyperglycemic mothers during 
pregnancy identified increased circulating levels of fructose, pentilols, and hexitols 
(Scholtens et al. 2014), similar to the significantly elevated hexitols (increased 3.9 and 2.1 
fold, respectively), pentilols (increased 3.7 fold), and fructose (increased 2.3 fold) in the 
present study (Figure 4B). While the role of hexitol/pentitol metabolism in the 
pathophysiology of diabetes is not clear, it has been proposed to play a role in clinical 
observations in diabetic patients ingesting the glucose substitute xylitol (Makinen 2000). A 
glycation product that has been found in neurofibrillary pathology of Alzheimer’s disease 
lesion is hexitol, where hexitol-lysine adducts form in a distinct oxidative process acting in 
concert with Alzheimer’s disease lesions (Castellani et al. 2001). Together, elevated fructose, 
pentilols, and hexitols found in HIP plasma may offer insight in the pathogenesis of multiple 
organs affected by hyperamylinemia and diabetes.
Conclusions
HIP hearts had significant DECREASES in five amino acids (lysine, alanine, tyrosine, 
phenylalanine, serine) and one significantly INCREASED amino acids (valine), which were 
unique from a T2D rat model. Additionally, The HIP rats exhibited a significant decrease in 
phenylalanine across all four tissues investigated, including plasma. This contrasts with the 
significantly INCREASED circulating phenylalanine reported in diabetics vs. controls in 
multiple recent studies (Kouzu et al. 2015; Tillin et al. 2015; Wurtz et al. 2015). 
DECREASED phenylalanine may serve as a unique marker of cardiac and brain dysfunction 
due to hyperamylinemia that can be differentiated from alterations in T2D in the plasma.
The deficiency in phenylalanine and tyrosine in HIP brains (<0.50 fold vs. wildtypeHIPTg+) 
is significant given their role in supporting brain chemistry. Tyrosine (and its precursor 
phenylalanine) in the brain function as precursors for catecholamines (dopamine, 
norepinephrine, epinephrine). While the deficiency in phenylalanine was seen across tissues 
including plasma and could be monitored, reduced tyrosine was seen only in the brain. The 
alterations in the pentose phosphate pathway (PPP) identified in the HIP brain (elevated 
glucose-6-phosphate and fructose-6-phosphate) have previously been seen in the brain in 
neurodegenerative diseases. Unlike most other cell types, neurons preferentially metabolize 
glucose using the pentose phosphate pathway to maintain their anti-oxidant status. However, 
altered glucose-6-phosphate was seen only in the heart and brain and was not detectable in 
the plasma.
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Non-standard abbreviations
AbetaPP amyloid beta protein precursor
GABA gamma-Aminobutyric acid
HIP rat model expressing pancreatic human amylin
hIAPP human islet amyloid polypeptide
PCA principal component analysis
PLS-DA partial least squares discriminant analysis
VIP variable importance in projection
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Figure 1. Non-targeted metabolomics of cardiac tissue in Human Amylin producing rat models 
(HIP rats)
A. Heat map of metabolites identified by non-targeted GC/MS analysis of cardiac tissue. B. 
Principal components analysis. C. Heat map comparing HIP to wildtypeHIPTg+ heart t-test 
significant metabolites and indicating fold change and false discovery rates (FDR) for each 
metabolite. D. Non-fasting glucose levels in HIP Tg+ rats. N=8/group. Data is mean +/− 
SEM.
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Figure 2. Non-targeted metabolomics of brain tissue in Human Amylin producing rat models 
(HIP rats)
A. Heat map of metabolites identified by non-targeted GC/MS analysis of brain tissue. B. 
Principal components analysis. C. Heat map comparing HIP to wildtypeHIPTg+ brain t-test 
significant metabolites and indicating fold change and false discovery rates (FDR) for each 
metabolite. N=10/group.
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Figure 3. Non-targeted metabolomics of liver tissue in Human Amylin producing rat models 
(HIP rats)
A. Heat map of metabolites identified by non-targeted GC/MS analysis of liver tissue. B. 
Principal components analysis. C. Heat map comparing HIP to wildtypeHIPTg+ liver t-test 
significant metabolites and indicating fold change and false discovery rates (FDR) for each 
metabolite. N=10/group.
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Figure 4. Non-targeted metabolomics of plasma in Human Amylin producing rat models (HIP 
rats)
A. Heat map of metabolites identified by non-targeted GC/MS analysis of plasma. B. 
Principal components analysis. C. Heat map comparing HIP to wildtypeHIPTg+ plasma t-test 
significant metabolites and indicating fold change and false discovery rates (FDR) for each 
metabolite. N= 10/group.
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Figure 5. Metabolic pathways affected in the hearts of HIP rats, determined by non-targeted 
metabolomics analysis
Metabolites were highlighted depending on their fold change compared to WT. Red 
highlight shows a decrease in fold change compared to WT. Blue Highlight shows an 
increase in fold change compared to wildtypeHIPTg+. A. TCA Cycle. B. Urea Cycle. C. 
Glycolysis. *Multiple species present. $involves multiple steps, not included.
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Figure 6. ANOVA significant metabolites found in three or tissues by Post-Hoc analysis across 
tissues
Box and whisper plot (indicating median, upper and lower quartile (box limits), and upper 
and lower extremes (error bars)) of fold change comparison between 8 groups with respect 
to A. Fumarate, B. Phenylalanine, C. α-Monstearin, and D. Uracil. A One-Way ANOVA 
was performed, with Fisher-LSD post-hoc comparisons made to the wildtypeHIPTg+ heart. 
**False discovery rate (FDR) ≤ 1.61 × e−7.
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Table 2
ANOVA significant metabolites found in two tissues by Post-Hoc analysis across tissues.
Metabolite
ANOVA Post-hoc
(FDR≤1.61 × e−7)
Heart
HIP vs. WT
Significant
Brain
HIP vs. WT
Significant
Liver
HIP vs. WT
Significant
Plasma
HIP vs. WT
Significant
Lysine
FDR=2.56 × e−29 ✻ ✻
Stearic acid
FDR=5.42 × e−20 ✻ ✻
Urea
FDR=8.46 × e−20 ✻ ✻
Glycerol-1-phosphate
FDR=1.35 × e−18 ✻ ✻
Glucose-6-phosphate
FDR=4.40 × e−11 ✻ ✻
Campesterol
FDR=7.82 × e−11 ✻ ✻
Docosahexaneoic acid
FDR=1.46 × e−9 ✻ ✻
Heptadecanoic acid/Octadecanol
FDR=1.61 × e−7 ✻ ✻
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